Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ARIAD Pharmaceuticals ARIA

Healthcare Biotechnology
"ARIAD Pharmaceuticals Inc is an oncology company. The Company is engaged in transforming the lives of cancer patients with breakthrough medicines. It commercializes & develops products and product candidates including Iclusig, Brigatinib, and AP32788."


NDAQ:ARIA - Post by User

ARIAD Pharmaceuticals
Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Post by EarningsImpact1on Jul 26, 2013 11:04am
430 Views
Post# 21632426

Very Insightful during Investor-and-Analyst-Meeting

Very Insightful during Investor-and-Analyst-Meeting Updates on clinical and safety data from the AP26113 trial & more.. 
[url=https://www.earningsimpact.com/Transcript/82369/ARIA/Ariad-Pharmaceuticals%2c-Inc----Investor-and-Analyst-Meeting]read here[/url]
Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities